Printer Friendly

ANGEION REPORTS THIRD QUARTER FIGURES

 ANGEION REPORTS THIRD QUARTER FIGURES
 MINNEAPOLIS, June 12 /PRNewswire/ -- Angeion Corporation


(NASDAQ: ANGN) reported sales of $1,869,768 for the third quarter ended April 30, 1992. This represents an eight percent decrease on sales of $2,039,960 for the third quarter ended April 30, 1991. Year-to-date sales were $4,697,996 compared to $4,697,992 for the same period last year.
 Angeion's research and development expenses for its AngeLase and AngeMed subsidiaries resulted in a loss of $895,456, or $.09 per share, for the third quarter ended April 30, 1992. This compares to a loss of $352,808, or $.04 per share for the third quarter ended April 30, 1991.
 "Year-to-date sales are nearly identical to sales for the same period last year," said Chairman and CEO Wendell L. King. "This is an accomplishment. The loss of a customer in July 1991 required a replacement of 34 percent of total sales for the nine month period. We've done a good job of replacing those sales with a mix of OEM and proprietary sales. Furthermore, we are achieving our goal of shifting our sales mix from OEM products to proprietary products. We've increased the proportion of proprietary product sales to 61 percent of total sales compared to 29 percent for the same quarter last year. Proprietary products provide Angeion with the ability to differentiate our products from competitors and offer the potential for improved profit margins. Angeion's Medical Products division also achieved its first profitable quarter.
 "In other areas, significant data is being accumulated in our ongoing clinical studies on the laser catheter product. Progress continues to be made on our fourth generation implantable defibrillator as well," added King.
 Angeion continues to work on two separate financing efforts: the sale of the Angeion Medical Products division and a corporate partner. The proceeds from Angeion's financing efforts will be used to fund its development of a laser catheter and implantable defibrillator to treat tachyarrhythmias.
 During the third quarter, Angeion also:
 -- Introduced its fifth family of proprietary products, the TYSHAK(TM) Pediatric Balloon Dilatation Catheter, which is available in 42 sizes. The device is used by pediatric interventional cardiologists. The product family has been well received by customers. With the addition of this product family, Angeion now offers more than 100 individual proprietary products, in addition to the more than 100 OEM products manufactured for medical company customers.
 -- Engaged Piper, Jaffray as its investment banker and to explore financing options including the possible sale of Angeion's Medical Products division.
 -- Was notified that three patents were issued and three patents were allowed on its laser catheter, mapping technology and biological pacemaker concept. Angeion's current patent position includes 14 patents issued and 65 patents pending or in process.
 -- Signed an exclusive agreement with a German company to distribute Angeion's five families of proprietary products.
 -- Was named to INC. magazine's list of 100 fastest-growing small public companies. Angeion was ranked number 27 on the list in recognition of its rapid growth rate in net sales during the last five years.
 Minneapolis-based Angeion Corporation is a manufacturer of cardiovascular products. Angeion's subsidiaries, AngeLase, Inc. and AngeMed, Inc., are developing products for treating various types of arrhythmias. Angeion is also traded on the Boston Stock Exchange under the symbol ANI.
 CONDENSED STATEMENTS OF OPERATIONS
 (Unaudited)
 Three Months Ended Nine Months Ended
 4/30/92 4/30/91 4/30/92 4/30/91
 Net sales $1,869,768 $2,039,960 $4,697,996 $4,697,992
 Net loss (895,456) (352,808)(3,000,027) (1,014,245)
 Loss per common share $(.09) $(.04) $(.31) $(.12)
 Weighted average
 number of shares
 outstanding 10,230,434 8,679,450 9,791,978 8,482,259
 CONDENSED BALANCE SHEETS
 (Unaudited)
 4/30/92 4/30/91
 Current assets $3,783,167 $3,089,862
 Property and other 2,984,464 2,255,775
 Total assets 6,767,631 5,345,637
 Current liabilities $1,081,594 $683,552
 Long-term debt 120,200 117,604
 Shareholders' equity 5,565,837 4,544,481
 Total liabilities & equity $6,767,631 $5,345,637
 -0- 6/12/92
 /CONTACT: Brenda Roth of Angeion, 612-550-9388/
 (ANGN) CO: Angeion Corporation ST: Minnesota IN: MTC SU: ERN


AL -- MN006 -- 9735 06/12/92 14:05 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 12, 1992
Words:715
Previous Article:BOOKER T. WASHINGTON HIGH SCHOOL 'KICKS BRAIN' IN THE 1992 TEXACO STAR NATIONAL ACADEMIC CHAMPIONSHIP AND WINS $50,000 IN SCHOLARSHIPS
Next Article:10TH ANNUAL MICHIGAN NEW PRODUCTS AWARD WINNERS SELECTED
Topics:


Related Articles
ANGEION REPORTS FIRST QUARTER SALES UP 13 PERCENT
ANGEION RELEASES SECOND QUARTER FIGURES
ANGEION REPORTS THIRD QUARTER FIGURES
ANGEION REPORTS FIRST QUARTER RESULTS
ANGEION REPORTS SECOND QUARTER RESULTS
ANGEION REPORTS THIRD QUARTER RESULTS; SECURES INITIAL BRIDGE LOAN
ANGEION REPORTS FIRST QUARTER RESULTS
ANGEION REPORTS THIRD QUARTER RESULTS
ANGEION REPORTS THIRD QUARTER RESULTS
Angeion Reports 33 Percent Growth in ICD Sales in Third Quarter.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters